Page last updated: 2024-09-03

gefitinib and azd3759

gefitinib has been researched along with azd3759 in 2 studies

Compound Research Comparison

Studies
(gefitinib)
Trials
(gefitinib)
Recent Studies (post-2010)
(gefitinib)
Studies
(azd3759)
Trials
(azd3759)
Recent Studies (post-2010) (azd3759)
5,2315662,91921121

Protein Interaction Comparison

ProteinTaxonomygefitinib (IC50)azd3759 (IC50)
Epidermal growth factor receptorHomo sapiens (human)0.0192
Receptor tyrosine-protein kinase erbB-2Homo sapiens (human)0.0033
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)0.622
D(2) dopamine receptorHomo sapiens (human)0.797
Receptor tyrosine-protein kinase erbB-3Homo sapiens (human)0.0033
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.156
Receptor tyrosine-protein kinase erbB-4Homo sapiens (human)0.0033

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, K; Cheng, Z; Johnström, P; Li, DY; Varnäs, K; Wang, J; Yang, ZF; Zeng, Q; Zhang, X1
Chen, GS; Chern, JW; Hsieh, CE; Liu, JR; Wu, KD1

Other Studies

2 other study(ies) available for gefitinib and azd3759

ArticleYear
Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
    Journal of medicinal chemistry, 2015, Oct-22, Volume: 58, Issue:20

    Topics: Animals; Brain; Brain Neoplasms; Central Nervous System; Clinical Trials, Phase I as Topic; Dogs; Drug Discovery; ErbB Receptors; Macaca fascicularis; Male; Mice; Piperazines; Positron-Emission Tomography; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Rats; Rats, Wistar; Xenograft Model Antitumor Assays

2015
Acrylamide Functional Group Incorporation Improves Drug-like Properties: An Example with EGFR Inhibitors.
    ACS medicinal chemistry letters, 2019, Jan-10, Volume: 10, Issue:1

    Topics:

2019